Briacell Therapeutics Corp. Common Shares - BCTX STOCK NEWS

AUSTIN, Texas, April 21, 2021, BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) announces a new interview with Dr. Bill Williams, discussing its targeted immunotherapies for breast cancer, focusing on its lead candidate, Bria-IMT™. This drug has shown positive proof-of-concept, improving survival rates for women with advanced breast cancer. Despite challenges from COVID-19, BriaCell uplisted to Nasdaq in February 2021 and raised $28.7 million to advance its projects, including a registration study for Bria-IMT™ and the development of other immunotherapies. Dr. Williams emphasizes the need for valuation reconsideration based on the company's advancements.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has expanded its investor outreach efforts to improve communication and enhance investor awareness regarding its clinical programs focused on advanced breast cancer. The company has engaged three firms: Core IR for investor relations, Investing News Network for advertising, and SmallCapVoice for online marketing. Core IR will receive a monthly retainer of $13,500, while INN is set for $68,000 semi-annually. Additionally, BriaCell has granted Core IR stock options for 60,000 shares at $4.24 each, vesting quarterly.

BriaCell Therapeutics Corp. (BCTX, BCTXW) has successfully completed the sale of an additional 882,352 shares at $4.24 each, generating approximately $3.7 million through the underwriter’s over-allotment option. This brings the total gross proceeds from the recent public offering to approximately $28.7 million. The funds will be allocated to clinical trials, R&D, and general corporate purposes. ThinkEquity, a division of Fordham Financial Management, served as the sole book-running manager for this offering.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) presented clinical trial data on Bria-IMT™ at the AACR Annual Meeting 2021. The results indicated significant disease control in advanced breast cancer patients, especially those with Grade I/II tumors. Key findings include:

• Median overall survival of 12.5 months for Grade I/II tumors vs. 7.2-9.8 months in recent studies.
• 67% disease control rate in Grade I/II patients with a median of 8 prior therapies.
• Prolonged progression-free survival of 8 months associated with a robust immune response.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2021, occurring in two parts from April 10-15 and May 17-21. The company will present data on its lead immunotherapy candidate, Bria-IMT™, focused on advanced breast cancer. Key findings include clinical and pathological analyses highlighting disease control and patient survival. Additionally, BriaCell approved the granting of 617,300 stock options to insiders, exercisable at $4.24 per share, vesting immediately, with a five-year expiration.

BriaCell Therapeutics Corp. has successfully closed its underwritten public offering, raising approximately US$25 million through the sale of 4,852,353 common units priced at US$4.25 per unit, and 1,030,000 pre-funded units at US$4.24 each. Each common unit includes one share of stock and one warrant, with a five-year exercise period. The funds will primarily support clinical trials and general working capital. Trading of the common shares and warrants began on February 24, 2021, under the symbols BCTX and BCTXW.

BriaCell Therapeutics Corp. has successfully closed its underwritten public offering, raising approximately US$25 million. The offering included 4,852,353 common units priced at US$4.25 per unit, plus 1,030,000 pre-funded units at US$4.24 per unit. The funds will be used for clinical trials, research, and general corporate activities. Additionally, the underwriter exercised its over-allotment option to purchase 882,352 warrants.

Common shares and warrants began trading on Nasdaq under symbols BCTX and BCTXW on February 24, 2021.

BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) announced a public offering of 5,882,353 units at $4.25 each, aiming to secure approximately $25 million in gross proceeds. Each unit consists of one share of common stock and one warrant, with the offering expected to close on February 26, 2021. The funds will support clinical trials and R&D, while warrants have an exercise price of $5.3125. The listing of common shares and warrants on NASDAQ is set for February 24, 2021. ThinkEquity is the sole book-running manager for this offering.

BriaCell Therapeutics Corp. has announced a public offering of 5,882,353 units, priced at US$4.25 each, to raise approximately US$25 million before expenses. Each unit comprises one share of common stock and one warrant, with warrants priced at US$5.3125 and exercisable for five years. The offering is set to close on February 26, 2021, subject to conditions. Funds will be allocated for clinical trials, research, and general corporate purposes. The securities are approved for trading on the Nasdaq under the symbols BCTX and BCTXW, starting February 24, 2021.